- Trials with a EudraCT protocol (229)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
229 result(s) found for: rare diseases.
Displaying page 1 of 12.
EudraCT Number: 2020-002821-28 | Sponsor Protocol Number: ET20-128 | Start Date*: 2020-12-24 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o... | ||
Medical condition: Metastatic or unresectable advanced rare sarcomas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002607-34 | Sponsor Protocol Number: GOIRC-02-2018CHANCETrial | Start Date*: 2019-02-20 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Phase II, open-label study of atezolizumab in a CoHort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histologiCal subtypEs – CHANCE trial | |||||||||||||
Medical condition: Advanced Non-small cell lung cancer (NSCLC) with rare histological subtypes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005269-37 | Sponsor Protocol Number: 836021009 | Start Date*: 2014-10-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS | ||
Medical condition: Patients with rare Immune mediated inflammatory diseases (IMIDs) involving the lungs causing interstitial pneumonitis (IP). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003311-19 | Sponsor Protocol Number: AIH-MAB | Start Date*: 2018-01-09 |
Sponsor Name:University Medical Centre Hamburg-Eppendorf | ||
Full Title: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximab AIH-MAB | ||
Medical condition: Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histol... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000793-27 | Sponsor Protocol Number: IRST100.42 | Start Date*: 2019-10-23 | |||||||||||||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||||||||||||
Full Title: A phase II study on adjuvant Vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: Head&Neck (H&N), neuroendocrine Tumors (NET) and soft tissue... | |||||||||||||||||||||||
Medical condition: Resected stage IV rare cancers: Head&Neck (H&N), neuroendocrine tumors (NET) and soft tissue sarcoma (STS). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002475-34 | Sponsor Protocol Number: REC0559-B-001 | Start Date*: 2020-03-03 | |||||||||||
Sponsor Name:Recordati Rare Diseases | |||||||||||||
Full Title: Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients | |||||||||||||
Medical condition: Neurotrophic Keratitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003853-70 | Sponsor Protocol Number: PNRR-MR1-2022-12375914 | Start Date*: 2023-05-02 | |||||||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi... | |||||||||||||||||||||||
Medical condition: Wolfram syndrome type 1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001478-78 | Sponsor Protocol Number: MCT8-2021-3 | Start Date*: 2023-03-31 |
Sponsor Name:Rare Thyroid Therapeutics International AB | ||
Full Title: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double blind, Randomized, Placebo controlled Study | ||
Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004281-19 | Sponsor Protocol Number: 1.5 | Start Date*: 2022-06-08 |
Sponsor Name:Region Stockholm Karolinska University Hospital (Dep. of Dermatology) | ||
Full Title: Investigator initiated clinical trial of dantrolene as a treatment for Darier disease | ||
Medical condition: Darier disease is a rare and severe autosomal dominant skin disorder. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024026-38 | Sponsor Protocol Number: mex201011 | Start Date*: 2012-01-10 |
Sponsor Name:Radboud University Nijmegen Medical Center | ||
Full Title: Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. | ||
Medical condition: Patients with non-dystrophic myotonic syndromes (NDMs). NDMs are caused by mutations in the gene encoding for the skeletal muscle sodium (SCN4A) or chloride (CLCN1) channel. In this study patient... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003957-25 | Sponsor Protocol Number: NAC2006 | Start Date*: 2006-10-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | |||||||||||||
Full Title: Rare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidly progressive diffuse Systemic Sclerosis (Scleroderma) | |||||||||||||
Medical condition: Systemic Scleroderma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004682-39 | Sponsor Protocol Number: KFJ-2020-02_NORMOSANG | Start Date*: 2020-11-16 |
Sponsor Name:Thomayerova nemocnice | ||
Full Title: Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease | ||
Medical condition: Patients with COVID -19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005856-12 | Sponsor Protocol Number: 20221 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Helsinki University Central Hospital | |||||||||||||
Full Title: Monoclonal gammopathies of renal significance (MGRS) in Finland | |||||||||||||
Medical condition: Rare renal diseases linked to monoclonal gammopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000513-14 | Sponsor Protocol Number: NBK154/2/2021 | Start Date*: 2023-03-08 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-b... | ||
Medical condition: Marfan Syndrome Diseases related to Marfan syndrome (rare diseases with aneurysms of the thoracic aorta and dissection of the aorta), among others: Loeys-Dietz syndrome, Vascular type of Ehlers-Da... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002222-23 | Sponsor Protocol Number: P170932J | Start Date*: 2019-02-05 |
Sponsor Name:APHP | ||
Full Title: Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study | ||
Medical condition: Histiocytoses are rare multisystemic disorders characterized by accumulation of histiocytes in various organs. patients with BRAF-wild type. | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000383-18 | Sponsor Protocol Number: LAL1913 | Start Date*: 2014-05-20 |
Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001719-65 | Sponsor Protocol Number: CALC-SSc | Start Date*: 2018-12-10 |
Sponsor Name:University Medial Center Groningen | ||
Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study | ||
Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002516-85 | Sponsor Protocol Number: 01-2011 | Start Date*: 2011-10-20 | |||||||||||
Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA | |||||||||||||
Full Title: Open-label study to evaluate the efficacy and tolerability of orally administered rosiglitazone in patients with progressive bone Fibrodysplasia (FOP) | |||||||||||||
Medical condition: Fibrodysplasia Ossificans Progressive (FOP) is a rare genetically based disability, characterized by progressive heterotopic ossification, usually associated with congenital malformation of the toes. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001382-10 | Sponsor Protocol Number: CS/2015/4775 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | |||||||||||||
Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service | |||||||||||||
Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001181-10 | Sponsor Protocol Number: P003077 | Start Date*: 2023-04-13 |
Sponsor Name:Medical Center - University of Freiburg | ||
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand... | ||
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.